Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial

被引：1
|
作者：
Sonpavde, Guru [1 ,2 ]
Pal, Sumanta [3 ]
机构：
[1] Univ Alabama UAB, Sch Med, Hematol Oncol Sect, Dept Med, Birmingham, AL USA
[2] Vet Affairs Med Ctr, Birmingham, AL USA
[3] City Hope Comprehens Canc Ctr, Dept Med, Hematol Oncol Sect, Duarte, CA USA
来源：
EUROPEAN UROLOGY | 2016年 / 70卷 / 01期
关键词：
CANCER;
D O I：
10.1016/j.eururo.2016.03.057
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 203
页数：1
相关论文
共 43 条
  • [1] Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
    Sternberg, Cora N.
    Skoneczna, Iwona
    Kerst, J. Martijn
    Albers, Peter
    Fossa, Sophie D.
    Agerbaek, Mads
    Dumez, Herlinde
    de Santis, Maria
    Theodore, Christine
    Leahy, Michael G.
    Chester, John D.
    Verbaeys, Antony
    Daugaard, Gedske
    Wood, Lori
    Witjes, J. Alfred
    de Wit, Ronald
    Geoffrois, Lionel
    Sengelov, Lisa
    Thalmann, George
    Charpentier, Danielle
    Rolland, Frederic
    Mignot, Laurent
    Sundar, Santhanam
    Symonds, Paul
    Graham, John
    Joly, Florence
    Marreaud, Sandrine
    Collette, Laurence
    Sylvester, Richard
    LANCET ONCOLOGY, 2015, 16 (01): : 76 - 86
  • [2] Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2016, 195 (01): : 63 - 64
  • [3] Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015;16:76-86
    Ohlmann, Carsten-Henning
    Stoeckle, Michael
    EUROPEAN UROLOGY, 2015, 68 (06) : 1104 - 1105
  • [4] Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ MO transitional cell carcinoma (TCC) of the bladder.
    Sternberg, Cora N.
    Skoneczna, Iwona Anna
    Kerst, Jan M.
    Fossa, Sophie D.
    Albers, Peter
    Agerbaek, Mads
    Dumez, Herlinde
    De Santis, Maria
    Theodore, Christine
    Leahy, Michael Gordon
    Chester, John D.
    Verbaeys, Antony
    Caty, Armelle
    Daugaard, Gedske
    Marreaud, Sandrine
    Cambier, Samantha
    Sylvester, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial
    Linares-Espinos, Estefania
    Sanchez-Salas, Rafael
    EUROPEAN UROLOGY, 2019, 75 (01) : 199 - 199
  • [6] Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial
    Giannarini, Gianluca
    Crestani, Alessandro
    Ficarra, Vincenzo
    EUROPEAN UROLOGY, 2018, 74 (06) : 840 - 841
  • [7] Adjuvant vs. progression-triggered treatment with gemcitabine after radical cystectomy in platinum-ineligible patients with pT3-pT4 or N+M0 urothelial carcinoma of the bladder (AUO-AB 22-00): Long-term follow-up of a randomized multicenter phase 3 trial
    Heinzelbecker, J.
    Spieler, N.
    Kuehn, M.
    Fischer, C.
    Volkmer, B.
    Von Rundstedt, F-C.
    Albers, P.
    Becht, E.
    Bannowsky, A.
    Weber, H. M.
    Hofmann, R.
    Mueller, M.
    Langbein, S.
    Steiner, G.
    Retz, M.
    Kamradt, J.
    Wellek, S.
    Lehmann, J.
    Stoeckle, M.
    EUROPEAN UROLOGY, 2021, 79 : S1152 - S1153
  • [8] Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial
    Afferi, Luca
    Moschini, Marco
    Mattei, Agostino
    Montorsi, Francesco
    Briganti, Alberto
    Cathelineau, Xavier
    Sanchez-Salas, Rafael
    EUROPEAN UROLOGY, 2020, 78 (02) : 289 - 290
  • [9] Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial
    D'Andrea, David
    Pradere, Benjamin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2021, 79 (01) : 163 - 164
  • [10] Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial
    Kuusk, Teele
    Bex, Axel
    EUROPEAN UROLOGY, 2020, 78 (04) : 630 - 631
12345